Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 543

1.

MD-Miner: a network-based approach for personalized drug repositioning.

Wu H, Miller E, Wijegunawardana D, Regan K, Payne PRO, Li F.

BMC Syst Biol. 2017 Oct 3;11(Suppl 5):86. doi: 10.1186/s12918-017-0462-9.

2.

High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer.

Williams SP, Barthorpe AS, Lightfoot H, Garnett MJ, McDermott U.

Sci Data. 2017 Oct 3;4:170139. doi: 10.1038/sdata.2017.139.

3.

In vitro anticancer drug test: A new method emerges from the model of glioma stem cells.

Riva G, Baronchelli S, Paoletta L, Butta V, Biunno I, Lavitrano M, Dalprà L, Bentivegna A.

Toxicol Rep. 2014 May 22;1:188-199. doi: 10.1016/j.toxrep.2014.05.005. eCollection 2014.

4.

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status.

Zhang J, Nannapaneni S, Wang D, Liu F, Wang X, Jin R, Liu X, Rahman MA, Peng X, Qian G, Chen ZG, Wong KK, Khuri FR, Zhou W, Shin DM.

Oncotarget. 2017 Aug 1;8(35):59008-59022. doi: 10.18632/oncotarget.19779. eCollection 2017 Aug 29.

5.

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.

Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, Klebl BM, Thomas RK, Sos ML.

Cell Rep. 2017 Sep 19;20(12):2833-2845. doi: 10.1016/j.celrep.2017.08.082.

6.

Revisiting inconsistency in large pharmacogenomic studies.

Safikhani Z, Smirnov P, Freeman M, El-Hachem N, She A, Rene Q, Goldenberg A, Birkbak NJ, Hatzis C, Shi L, Beck AH, Aerts HJWL, Quackenbush J, Haibe-Kains B.

Version 3. F1000Res. 2016 Sep 16 [revised 2017 Jan 1];5:2333. doi: 10.12688/f1000research.9611.3. eCollection 2016.

7.

Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.

John BA, Said N.

Oncotarget. 2017 May 9;8(34):57766-57781. doi: 10.18632/oncotarget.17714. eCollection 2017 Aug 22. Review.

8.

ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.

Gharibi A, La Kim S, Molnar J, Brambilla D, Adamian Y, Hoover M, Hong J, Lin J, Wolfenden L, Kelber JA.

Sci Rep. 2017 Aug 30;7(1):10060. doi: 10.1038/s41598-017-09946-z.

9.

Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.

Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M, Price S, Wright JC, Yu L, Yang M, Dienstmann R, Guinney J, Beltrao P, Brazma A, Pardo M, Stegle O, Adams DJ, Wessels L, Saez-Rodriguez J, McDermott U, Choudhary JS.

Cell Rep. 2017 Aug 29;20(9):2201-2214. doi: 10.1016/j.celrep.2017.08.010.

10.

Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.

Geeleher P, Zhang Z, Wang F, Gruener RF, Nath A, Morrison G, Bhutra S, Grossman RL, Huang RS.

Genome Res. 2017 Oct;27(10):1743-1751. doi: 10.1101/gr.221077.117. Epub 2017 Aug 28.

PMID:
28847918
11.

Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States.

Kim JW, Abudayyeh OO, Yeerna H, Yeang CH, Stewart M, Jenkins RW, Kitajima S, Konieczkowski DJ, Medetgul-Ernar K, Cavazos T, Mah C, Ting S, Van Allen EM, Cohen O, Mcdermott J, Damato E, Aguirre AJ, Liang J, Liberzon A, Alexe G, Doench J, Ghandi M, Vazquez F, Weir BA, Tsherniak A, Subramanian A, Meneses-Cime K, Park J, Clemons P, Garraway LA, Thomas D, Boehm JS, Barbie DA, Hahn WC, Mesirov JP, Tamayo P.

Cell Syst. 2017 Aug 23;5(2):105-118.e9. doi: 10.1016/j.cels.2017.08.002.

PMID:
28837809
12.

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.

Lim JSJ, Tan DSP.

Cancers (Basel). 2017 Aug 22;9(8). pii: E109. doi: 10.3390/cancers9080109. Review.

13.

Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.

Emad A, Cairns J, Kalari KR, Wang L, Sinha S.

Genome Biol. 2017 Aug 11;18(1):153. doi: 10.1186/s13059-017-1282-3.

14.

The effect of Nullomer-derived peptides 9R, 9S1R and 124R on the NCI-60 panel and normal cell lines.

Alileche A, Hampikian G.

BMC Cancer. 2017 Aug 9;17(1):533. doi: 10.1186/s12885-017-3514-z.

15.

A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.

Covell DG.

PLoS One. 2017 Aug 8;12(8):e0181991. doi: 10.1371/journal.pone.0181991. eCollection 2017.

16.

Functional proteomic characterization of cancer cell lines.

Zhao W, Li J, Mills GB.

Oncoscience. 2017 Jun 10;4(5-6):41-42. doi: 10.18632/oncoscience.351. eCollection 2017 May. No abstract available.

17.

Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.

Wang L, Li X, Zhang L, Gao Q.

BMC Cancer. 2017 Aug 2;17(1):513. doi: 10.1186/s12885-017-3500-5.

18.

CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer.

Bridgett S, Campbell J, Lord CJ, Ryan CJ.

Cell Syst. 2017 Jul 26;5(1):82-86.e3. doi: 10.1016/j.cels.2017.06.002. Epub 2017 Jul 12.

19.

Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets.

Chen B, Ma L, Paik H, Sirota M, Wei W, Chua MS, So S, Butte AJ.

Nat Commun. 2017 Jul 12;8:16022. doi: 10.1038/ncomms16022.

20.

Crosstalk and the evolvability of intracellular communication.

Rowland MA, Greenbaum JM, Deeds EJ.

Nat Commun. 2017 Jul 10;8:16009. doi: 10.1038/ncomms16009.

Supplemental Content

Support Center